Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sepsis | 13 | 2024 | 102 | 3.730 |
Why?
|
Critical Care | 19 | 2025 | 52 | 3.480 |
Why?
|
Critical Illness | 9 | 2025 | 44 | 3.270 |
Why?
|
Intensive Care Units | 17 | 2025 | 66 | 2.980 |
Why?
|
Developing Countries | 6 | 2025 | 400 | 1.300 |
Why?
|
Humans | 58 | 2025 | 14537 | 1.260 |
Why?
|
Fluid Therapy | 8 | 2025 | 25 | 1.210 |
Why?
|
Infection Control | 4 | 2021 | 31 | 1.120 |
Why?
|
Pandemics | 6 | 2022 | 296 | 1.100 |
Why?
|
Shock, Septic | 5 | 2024 | 10 | 1.090 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 104 | 1.080 |
Why?
|
Practice Guidelines as Topic | 8 | 2021 | 127 | 1.070 |
Why?
|
Health Resources | 5 | 2024 | 66 | 1.050 |
Why?
|
Anti-Bacterial Agents | 6 | 2024 | 293 | 1.030 |
Why?
|
Coronavirus Infections | 3 | 2020 | 71 | 0.970 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 1 | 0.780 |
Why?
|
Consensus | 4 | 2024 | 62 | 0.740 |
Why?
|
Inflammation | 1 | 2021 | 104 | 0.740 |
Why?
|
Malaria | 3 | 2020 | 213 | 0.730 |
Why?
|
Tertiary Care Centers | 2 | 2021 | 80 | 0.720 |
Why?
|
Quality Improvement | 1 | 2020 | 34 | 0.700 |
Why?
|
Intensive Care Units, Neonatal | 2 | 2019 | 17 | 0.570 |
Why?
|
Healthcare Disparities | 1 | 2017 | 43 | 0.550 |
Why?
|
Hemoglobins | 1 | 2016 | 40 | 0.530 |
Why?
|
Survival Rate | 2 | 2016 | 96 | 0.530 |
Why?
|
Hospital Mortality | 1 | 2016 | 95 | 0.530 |
Why?
|
Betacoronavirus | 3 | 2020 | 52 | 0.520 |
Why?
|
Patient Discharge | 1 | 2016 | 27 | 0.520 |
Why?
|
Drug Resistance, Bacterial | 2 | 2017 | 135 | 0.510 |
Why?
|
Hospitalization | 3 | 2021 | 418 | 0.500 |
Why?
|
Infant, Newborn, Diseases | 1 | 2016 | 73 | 0.500 |
Why?
|
Antitubercular Agents | 1 | 2018 | 322 | 0.490 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 57 | 0.480 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2018 | 324 | 0.470 |
Why?
|
Delphi Technique | 3 | 2024 | 30 | 0.470 |
Why?
|
Oxygen | 4 | 2023 | 25 | 0.450 |
Why?
|
Anticoagulants | 4 | 2025 | 57 | 0.420 |
Why?
|
Venous Thromboembolism | 3 | 2025 | 27 | 0.420 |
Why?
|
Tuberculosis | 1 | 2018 | 543 | 0.400 |
Why?
|
Microbial Sensitivity Tests | 2 | 2019 | 198 | 0.400 |
Why?
|
Ceftriaxone | 1 | 2012 | 13 | 0.390 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 244 | 0.390 |
Why?
|
Bacteria | 1 | 2012 | 47 | 0.380 |
Why?
|
Lactic Acid | 3 | 2025 | 34 | 0.330 |
Why?
|
Male | 14 | 2025 | 6754 | 0.320 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2019 | 37 | 0.320 |
Why?
|
South Africa | 11 | 2021 | 7596 | 0.320 |
Why?
|
Silver Sulfadiazine | 1 | 2008 | 1 | 0.310 |
Why?
|
Catheterization, Central Venous | 1 | 2008 | 2 | 0.310 |
Why?
|
Chlorhexidine | 1 | 2008 | 10 | 0.310 |
Why?
|
Anti-Infective Agents, Local | 1 | 2008 | 16 | 0.310 |
Why?
|
Adult | 13 | 2024 | 5913 | 0.290 |
Why?
|
Female | 15 | 2025 | 9103 | 0.290 |
Why?
|
Infant, Newborn | 5 | 2019 | 1479 | 0.280 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2025 | 11 | 0.270 |
Why?
|
Oxygen Inhalation Therapy | 3 | 2023 | 13 | 0.270 |
Why?
|
Aged | 6 | 2020 | 1740 | 0.270 |
Why?
|
Middle Aged | 10 | 2020 | 3601 | 0.260 |
Why?
|
Research Design | 3 | 2021 | 124 | 0.260 |
Why?
|
Drug Administration Routes | 3 | 2021 | 8 | 0.250 |
Why?
|
Infant | 5 | 2018 | 2244 | 0.250 |
Why?
|
Nutrition Therapy | 1 | 2025 | 4 | 0.240 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 156 | 0.240 |
Why?
|
Acetates | 1 | 2025 | 7 | 0.240 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2021 | 11 | 0.240 |
Why?
|
Palliative Care | 1 | 2024 | 52 | 0.230 |
Why?
|
Respiratory Insufficiency | 2 | 2021 | 17 | 0.230 |
Why?
|
Terminal Care | 1 | 2024 | 35 | 0.230 |
Why?
|
Nutritional Status | 1 | 2025 | 76 | 0.230 |
Why?
|
Child | 4 | 2018 | 2242 | 0.220 |
Why?
|
Retrospective Studies | 6 | 2019 | 799 | 0.220 |
Why?
|
Attitude of Health Personnel | 1 | 2025 | 106 | 0.220 |
Why?
|
Health Personnel | 2 | 2022 | 231 | 0.210 |
Why?
|
Pneumonia | 1 | 2024 | 131 | 0.210 |
Why?
|
Enterobacteriaceae | 2 | 2019 | 11 | 0.210 |
Why?
|
Risk Factors | 5 | 2021 | 1475 | 0.210 |
Why?
|
Global Health | 2 | 2024 | 193 | 0.200 |
Why?
|
Resuscitation | 2 | 2021 | 18 | 0.200 |
Why?
|
Advisory Committees | 2 | 2018 | 14 | 0.190 |
Why?
|
Chemokines | 1 | 2021 | 9 | 0.190 |
Why?
|
Aged, 80 and over | 2 | 2016 | 468 | 0.190 |
Why?
|
Antimicrobial Stewardship | 2 | 2019 | 14 | 0.190 |
Why?
|
Candidemia | 1 | 2021 | 13 | 0.190 |
Why?
|
Thrombocytopenia | 1 | 2021 | 11 | 0.190 |
Why?
|
Erythrocyte Transfusion | 2 | 2021 | 6 | 0.190 |
Why?
|
Cytokines | 1 | 2021 | 107 | 0.180 |
Why?
|
Communicable Diseases | 2 | 2019 | 62 | 0.180 |
Why?
|
Oxygenators | 1 | 2020 | 2 | 0.180 |
Why?
|
Thrombosis | 1 | 2021 | 47 | 0.180 |
Why?
|
Hospital Administration | 1 | 2020 | 3 | 0.180 |
Why?
|
Cross-Sectional Studies | 4 | 2019 | 1422 | 0.180 |
Why?
|
Clinical Protocols | 1 | 2020 | 26 | 0.180 |
Why?
|
Young Adult | 4 | 2018 | 2498 | 0.180 |
Why?
|
Renal Dialysis | 1 | 2020 | 27 | 0.180 |
Why?
|
Adolescent | 5 | 2018 | 2985 | 0.180 |
Why?
|
Lung Diseases, Obstructive | 1 | 2000 | 5 | 0.180 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 112 | 0.180 |
Why?
|
Prospective Studies | 5 | 2021 | 1160 | 0.180 |
Why?
|
Child, Preschool | 4 | 2018 | 1748 | 0.170 |
Why?
|
Home Care Services | 1 | 2000 | 15 | 0.170 |
Why?
|
Infant, Very Low Birth Weight | 2 | 2019 | 21 | 0.170 |
Why?
|
Mucormycosis | 1 | 2019 | 3 | 0.170 |
Why?
|
Health Priorities | 1 | 2020 | 62 | 0.170 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2015 | 125 | 0.160 |
Why?
|
Neonatal Sepsis | 1 | 2019 | 29 | 0.160 |
Why?
|
Severity of Illness Index | 4 | 2021 | 253 | 0.160 |
Why?
|
Anti-Infective Agents | 3 | 2021 | 57 | 0.160 |
Why?
|
Expert Testimony | 1 | 2018 | 2 | 0.160 |
Why?
|
Cause of Death | 2 | 2019 | 221 | 0.160 |
Why?
|
Shock | 1 | 2018 | 4 | 0.160 |
Why?
|
Chickenpox | 1 | 1998 | 2 | 0.160 |
Why?
|
Patient Care Bundles | 1 | 2018 | 6 | 0.160 |
Why?
|
Inservice Training | 1 | 2018 | 7 | 0.150 |
Why?
|
Family | 1 | 2018 | 35 | 0.150 |
Why?
|
Glucocorticoids | 1 | 1998 | 20 | 0.150 |
Why?
|
Surveys and Questionnaires | 3 | 2025 | 563 | 0.150 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 3 | 0.150 |
Why?
|
Calcium-Binding Proteins | 1 | 2018 | 4 | 0.150 |
Why?
|
Nerve Tissue Proteins | 1 | 2018 | 18 | 0.150 |
Why?
|
DNA-Binding Proteins | 1 | 2018 | 20 | 0.150 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 38 | 0.150 |
Why?
|
Klebsiella | 2 | 2019 | 6 | 0.140 |
Why?
|
Escherichia coli | 2 | 2019 | 30 | 0.140 |
Why?
|
Severe Dengue | 1 | 2016 | 1 | 0.140 |
Why?
|
Patient Admission | 1 | 2016 | 11 | 0.140 |
Why?
|
Blood Substitutes | 1 | 2016 | 2 | 0.140 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2016 | 2 | 0.140 |
Why?
|
Organ Dysfunction Scores | 3 | 2021 | 3 | 0.140 |
Why?
|
Cattle | 1 | 2016 | 28 | 0.140 |
Why?
|
Reproducibility of Results | 2 | 2021 | 217 | 0.140 |
Why?
|
Atherosclerosis | 1 | 2018 | 100 | 0.130 |
Why?
|
Respiration, Artificial | 3 | 2021 | 47 | 0.130 |
Why?
|
Poverty | 1 | 2017 | 152 | 0.130 |
Why?
|
Health Care Costs | 1 | 2017 | 115 | 0.130 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 158 | 0.130 |
Why?
|
Birth Weight | 1 | 2016 | 80 | 0.130 |
Why?
|
Africa South of the Sahara | 1 | 2016 | 353 | 0.120 |
Why?
|
Internationality | 2 | 2025 | 36 | 0.120 |
Why?
|
Incidence | 2 | 2015 | 685 | 0.120 |
Why?
|
Population Surveillance | 1 | 2016 | 325 | 0.120 |
Why?
|
Animals | 1 | 2016 | 1081 | 0.110 |
Why?
|
Diagnosis, Differential | 3 | 2021 | 63 | 0.110 |
Why?
|
Vena Cava Filters | 1 | 2013 | 4 | 0.110 |
Why?
|
Preoperative Care | 1 | 2013 | 9 | 0.110 |
Why?
|
Cross Infection | 2 | 2006 | 52 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2013 | 20 | 0.110 |
Why?
|
HIV Infections | 2 | 2021 | 5097 | 0.100 |
Why?
|
Hospitals, Private | 1 | 2012 | 8 | 0.100 |
Why?
|
Hemorrhage | 1 | 2013 | 72 | 0.100 |
Why?
|
Physicians | 2 | 2025 | 31 | 0.100 |
Why?
|
Citrobacter | 1 | 2012 | 1 | 0.100 |
Why?
|
Viridans Streptococci | 1 | 2012 | 1 | 0.100 |
Why?
|
Practice Patterns, Physicians' | 1 | 2012 | 43 | 0.100 |
Why?
|
Societies, Medical | 2 | 2024 | 26 | 0.100 |
Why?
|
Immunoglobulins | 2 | 2021 | 11 | 0.100 |
Why?
|
Bacterial Infections | 1 | 2012 | 54 | 0.100 |
Why?
|
Electronic Health Records | 2 | 2021 | 10 | 0.100 |
Why?
|
Reference Values | 2 | 2021 | 64 | 0.100 |
Why?
|
Haemophilus influenzae | 1 | 2012 | 42 | 0.100 |
Why?
|
Staphylococcus aureus | 1 | 2012 | 43 | 0.100 |
Why?
|
Time-to-Treatment | 2 | 2021 | 42 | 0.090 |
Why?
|
Arterial Pressure | 2 | 2021 | 35 | 0.090 |
Why?
|
Symptom Assessment | 2 | 2020 | 16 | 0.090 |
Why?
|
Heparin | 1 | 2010 | 5 | 0.090 |
Why?
|
Biomarkers | 2 | 2021 | 327 | 0.090 |
Why?
|
Asthma | 1 | 2010 | 33 | 0.090 |
Why?
|
Patient Education as Topic | 2 | 2007 | 48 | 0.080 |
Why?
|
Blood Glucose | 2 | 2021 | 107 | 0.080 |
Why?
|
Rwanda | 2 | 2018 | 30 | 0.080 |
Why?
|
Evidence-Based Medicine | 2 | 2018 | 34 | 0.080 |
Why?
|
Hospitals, Special | 1 | 2007 | 4 | 0.070 |
Why?
|
Health Services Accessibility | 2 | 2020 | 280 | 0.070 |
Why?
|
Thromboembolism | 1 | 2007 | 10 | 0.070 |
Why?
|
Feasibility Studies | 2 | 2018 | 101 | 0.070 |
Why?
|
Warfarin | 1 | 2007 | 19 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2008 | 272 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 253 | 0.070 |
Why?
|
Disease Management | 2 | 2019 | 74 | 0.070 |
Why?
|
Treatment Outcome | 2 | 2018 | 889 | 0.060 |
Why?
|
Communicable Disease Control | 1 | 2006 | 101 | 0.060 |
Why?
|
Anesthesiologists | 1 | 2025 | 1 | 0.060 |
Why?
|
Buffers | 1 | 2025 | 1 | 0.060 |
Why?
|
Isotonic Solutions | 1 | 2025 | 6 | 0.060 |
Why?
|
Europe | 1 | 2024 | 56 | 0.060 |
Why?
|
Communication | 1 | 2024 | 57 | 0.060 |
Why?
|
Decision Making | 1 | 2024 | 53 | 0.060 |
Why?
|
Databases, Factual | 1 | 2024 | 64 | 0.060 |
Why?
|
Income | 1 | 2024 | 85 | 0.060 |
Why?
|
Vasoconstrictor Agents | 1 | 2021 | 6 | 0.050 |
Why?
|
Cardiotonic Agents | 1 | 2021 | 8 | 0.050 |
Why?
|
Renal Replacement Therapy | 1 | 2021 | 6 | 0.050 |
Why?
|
Personal Protective Equipment | 1 | 2021 | 16 | 0.050 |
Why?
|
Hemodynamics | 1 | 2021 | 32 | 0.050 |
Why?
|
Multiple Organ Failure | 1 | 2021 | 4 | 0.050 |
Why?
|
Dyspnea | 1 | 2021 | 10 | 0.050 |
Why?
|
Recovery of Function | 1 | 2021 | 11 | 0.050 |
Why?
|
Equipment Reuse | 1 | 2020 | 2 | 0.050 |
Why?
|
Blood Physiological Phenomena | 1 | 2020 | 3 | 0.050 |
Why?
|
Equipment Design | 1 | 2020 | 27 | 0.050 |
Why?
|
Partial Pressure | 1 | 2000 | 1 | 0.040 |
Why?
|
Vital Capacity | 1 | 2000 | 6 | 0.040 |
Why?
|
Forced Expiratory Volume | 1 | 2000 | 9 | 0.040 |
Why?
|
Models, Biological | 1 | 2020 | 77 | 0.040 |
Why?
|
Ebolavirus | 1 | 2000 | 4 | 0.040 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2000 | 9 | 0.040 |
Why?
|
Lung | 1 | 2000 | 70 | 0.040 |
Why?
|
Proteus mirabilis | 1 | 2019 | 2 | 0.040 |
Why?
|
Serratia marcescens | 1 | 2019 | 3 | 0.040 |
Why?
|
Enterobacter cloacae | 1 | 2019 | 3 | 0.040 |
Why?
|
Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 6 | 0.040 |
Why?
|
Africa | 1 | 2021 | 376 | 0.040 |
Why?
|
Patient Compliance | 1 | 2000 | 120 | 0.040 |
Why?
|
Infant, Premature | 1 | 2019 | 56 | 0.040 |
Why?
|
Klebsiella pneumoniae | 1 | 2019 | 39 | 0.040 |
Why?
|
Disease Outbreaks | 1 | 2000 | 111 | 0.040 |
Why?
|
Carbapenems | 1 | 2019 | 17 | 0.040 |
Why?
|
Central Venous Pressure | 1 | 2018 | 2 | 0.040 |
Why?
|
Monitoring, Physiologic | 1 | 2018 | 25 | 0.040 |
Why?
|
Professional-Family Relations | 1 | 2018 | 4 | 0.040 |
Why?
|
Blood Gas Analysis | 1 | 1998 | 3 | 0.040 |
Why?
|
Heart Rate | 1 | 2018 | 32 | 0.040 |
Why?
|
Herpesvirus 3, Human | 1 | 1998 | 3 | 0.040 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2018 | 4 | 0.040 |
Why?
|
Body Temperature | 1 | 2018 | 7 | 0.040 |
Why?
|
Controlled Before-After Studies | 1 | 2018 | 1 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2018 | 13 | 0.040 |
Why?
|
Acyclovir | 1 | 1998 | 11 | 0.040 |
Why?
|
Medically Underserved Area | 1 | 2018 | 13 | 0.040 |
Why?
|
Hospitals, District | 1 | 2018 | 5 | 0.040 |
Why?
|
Patient Safety | 1 | 2018 | 9 | 0.040 |
Why?
|
Length of Stay | 1 | 2018 | 43 | 0.040 |
Why?
|
Radiography | 1 | 1998 | 80 | 0.040 |
Why?
|
Acute Disease | 1 | 2018 | 105 | 0.040 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2018 | 11 | 0.040 |
Why?
|
Carotid Arteries | 1 | 2018 | 19 | 0.040 |
Why?
|
Drug Resistance, Multiple | 1 | 2017 | 6 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 40 | 0.040 |
Why?
|
Rheumatoid Factor | 1 | 2018 | 16 | 0.040 |
Why?
|
Plaque, Atherosclerotic | 1 | 2018 | 27 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2021 | 239 | 0.040 |
Why?
|
Glomerular Filtration Rate | 1 | 2018 | 62 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 1998 | 279 | 0.040 |
Why?
|
Antiviral Agents | 1 | 1998 | 111 | 0.040 |
Why?
|
Carotid Intima-Media Thickness | 1 | 2018 | 108 | 0.040 |
Why?
|
Global Burden of Disease | 1 | 2017 | 5 | 0.040 |
Why?
|
Drug Resistance | 1 | 2017 | 35 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2017 | 62 | 0.030 |
Why?
|
Antimalarials | 1 | 2016 | 33 | 0.030 |
Why?
|
Biomedical Research | 1 | 2017 | 49 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 411 | 0.030 |
Why?
|
Malaria, Falciparum | 1 | 2016 | 39 | 0.030 |
Why?
|
Blood Pressure | 1 | 2018 | 317 | 0.030 |
Why?
|
Body Mass Index | 1 | 2018 | 321 | 0.030 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 1996 | 35 | 0.030 |
Why?
|
Cohort Studies | 1 | 2019 | 967 | 0.030 |
Why?
|
Dabigatran | 1 | 2013 | 3 | 0.030 |
Why?
|
beta-Alanine | 1 | 2013 | 3 | 0.030 |
Why?
|
Thiophenes | 1 | 2013 | 4 | 0.030 |
Why?
|
Rivaroxaban | 1 | 2013 | 6 | 0.030 |
Why?
|
Morpholines | 1 | 2013 | 5 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2013 | 13 | 0.030 |
Why?
|
International Normalized Ratio | 1 | 2013 | 17 | 0.030 |
Why?
|
Drug Substitution | 1 | 2013 | 33 | 0.030 |
Why?
|
Chemoprevention | 1 | 2013 | 33 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2013 | 55 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2012 | 9 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2012 | 26 | 0.030 |
Why?
|
Risk Assessment | 1 | 2013 | 225 | 0.020 |
Why?
|
Hospitals, Public | 1 | 2012 | 45 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2012 | 43 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 507 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2013 | 252 | 0.020 |
Why?
|
Medicine in the Arts | 1 | 2009 | 3 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2010 | 480 | 0.020 |
Why?
|
Prevalence | 1 | 2012 | 1192 | 0.020 |
Why?
|
Pregnancy | 1 | 2007 | 1862 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2000 | 21 | 0.010 |
Why?
|
APACHE | 1 | 1996 | 12 | 0.010 |
Why?
|
Prognosis | 1 | 1996 | 199 | 0.010 |
Why?
|